Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADPT Adaptive Biotechnologies	$13.00 +2.7%	$11.09	$3.98 ▼ $13.37	$1.98B	1.92	2.05 million shs	2.36 million shs
CGON CG Oncology	$26.49 +6.2%	$26.20	$14.80 ▼ $40.47	$2.02B	0.87	1.00 million shs	660,099 shs
SLDB Solid Biosciences	$6.68 +10.6%	$5.50	$2.41 ▼ $10.37	$517.80M	2.44	1.95 million shs	1.45 million shs
VCEL Vericel	$37.93 +3.8%	$40.02	$33.09 ▼ $63.00	$1.91B	1.27	500,845 shs	618,228 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADPT Adaptive Biotechnologies	+4.20%	+14.57%	+7.11%	+40.04%	+194.42%
CGON CG Oncology	+4.22%	-7.39%	-6.62%	+3.23%	-24.16%
SLDB Solid Biosciences	-0.59%	-9.85%	+14.83%	+136.86%	-15.64%
VCEL Vericel	+3.13%	-0.76%	-8.49%	-13.62%	-19.60%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADPT Adaptive Biotechnologies	2.874 of 5 stars	1.4	2.0	4.2	2.1	2.5	0.6
CGON CG Oncology	1.919 of 5 stars	3.5	2.0	0.0	2.8	0.8	0.0
SLDB Solid Biosciences	3.4595 of 5 stars	4.6	1.0	0.0	3.1	2.5	0.6
VCEL Vericel	2.3616 of 5 stars	3.5	0.0	0.0	3.4	0.0	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADPT Adaptive Biotechnologies	2.88	Moderate Buy	$12.38	-4.81% Downside
CGON CG Oncology	3.08	Buy	$55.30	108.76% Upside
SLDB Solid Biosciences	3.17	Buy	$14.80	121.56% Upside
VCEL Vericel	3.00	Buy	$60.33	59.06% Upside

Current Analyst Ratings Breakdown

Latest SLDB, CGON, ADPT, and VCEL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	SLDB Solid Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$17.00 ➝ $14.00
8/6/2025	ADPT Adaptive Biotechnologies	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$10.00 ➝ $14.00
8/6/2025	ADPT Adaptive Biotechnologies	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $15.00
8/6/2025	ADPT Adaptive Biotechnologies	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$13.00 ➝ $15.00
8/1/2025	VCEL Vericel	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$61.00 ➝ $58.00
7/21/2025	SLDB Solid Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$16.00
7/16/2025	CGON CG Oncology	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$68.00 ➝ $53.00
7/10/2025	CGON CG Oncology	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$40.00
6/26/2025	SLDB Solid Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
6/26/2025	SLDB Solid Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
6/18/2025	ADPT Adaptive Biotechnologies	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADPT Adaptive Biotechnologies	$205.22M	9.65	N/A	N/A	$1.18 per share	11.02
CGON CG Oncology	$1.14M	1,771.81	N/A	N/A	$8.79 per share	3.01
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	$3.43 per share	N/A
VCEL Vericel	$237.22M	8.07	$0.33 per share	113.38	$6.08 per share	6.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADPT Adaptive Biotechnologies	-$159.49M	-$0.82	N/A	N/A	N/A	-59.07%	-60.93%	-23.03%	N/A
CGON CG Oncology	-$88.04M	-$1.77	N/A	N/A	N/A	-15,945.17%	-19.37%	-18.72%	8/14/2025 (Estimated)
SLDB Solid Biosciences	-$124.70M	-$2.99	N/A	N/A	N/A	N/A	-68.15%	-55.33%	N/A
VCEL Vericel	$10.36M	$0.12	316.11	86.20	N/A	2.85%	2.47%	1.69%	N/A

Latest SLDB, CGON, ADPT, and VCEL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	SLDB Solid Biosciences	-$0.51	-$0.42	+$0.09	-$0.42	N/A	N/A
8/8/2025	Q2 2025	CGON CG Oncology	-$0.49	-$0.54	-$0.05	-$0.54	$0.11 million	N/A
8/5/2025	Q2 2025	ADPT Adaptive Biotechnologies	-$0.24	-$0.17	+$0.07	-$0.17	$49.40 million	$49.94 million
7/31/2025	Q2 2025	VCEL Vericel	-$0.04	-$0.01	+$0.03	-$0.01	$64.61 million	$63.24 million
5/15/2025	Q1 2025	SLDB Solid Biosciences	-$0.53	-$0.59	-$0.06	-$0.59	N/A	N/A
5/13/2025	Q1 2025	CGON CG Oncology	-$0.36	-$0.45	-$0.09	-$0.45	$0.53 million	$0.05 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADPT Adaptive Biotechnologies	N/A	N/A	N/A	N/A	N/A
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	N/A
VCEL Vericel	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADPT Adaptive Biotechnologies	N/A	2.84	2.75
CGON CG Oncology	N/A	22.15	30.97
SLDB Solid Biosciences	N/A	10.89	10.89
VCEL Vericel	N/A	4.97	4.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADPT Adaptive Biotechnologies	99.17%
CGON CG Oncology	26.56%
SLDB Solid Biosciences	81.46%
VCEL Vericel	N/A

Insider Ownership

Company	Insider Ownership
ADPT Adaptive Biotechnologies	6.40%
CGON CG Oncology	N/A
SLDB Solid Biosciences	13.63%
VCEL Vericel	7.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADPT Adaptive Biotechnologies	790	152.27 million	142.53 million	Optionable
CGON CG Oncology	61	76.25 million	N/A	Optionable
SLDB Solid Biosciences	100	77.52 million	66.95 million	Optionable
VCEL Vericel	300	50.46 million	46.83 million	Optionable

SLDB, CGON, ADPT, and VCEL Headlines

Recent News About These Companies

Townsquare Capital LLC Purchases 7,312 Shares of Vericel Corporation (NASDAQ:VCEL)

August 13 at 4:25 AM | marketbeat.com

Vericel (VCEL) Receives a Buy from Canaccord Genuity

August 12 at 9:08 PM | theglobeandmail.com

Global Alpha Capital Management Ltd. Boosts Stock Holdings in Vericel Corporation (NASDAQ:VCEL)

August 10 at 7:55 AM | marketbeat.com

Zions Bancorporation National Association UT Makes New Investment in Vericel Corporation (NASDAQ:VCEL)

August 10 at 5:59 AM | marketbeat.com

CenterBook Partners LP Invests $888,000 in Vericel Corporation (NASDAQ:VCEL)

August 9, 2025 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Shares Purchased by Mutual of America Capital Management LLC

August 8, 2025 | marketbeat.com

Vericel Q2 Revenue Jumps 20%

August 5, 2025 | fool.com

Vericel Corporation (NASDAQ:VCEL) Short Interest Up 308.4% in July

August 5, 2025 | americanbankingnews.com

Vericel FY2025 EPS Forecast Decreased by Leerink Partnrs

August 5, 2025 | americanbankingnews.com

Vericel Corporation (NASDAQ:VCEL) Shares Purchased by Geneva Capital Management LLC

August 4, 2025 | marketbeat.com

Canaccord Genuity Group Cuts Vericel (NASDAQ:VCEL) Price Target to $58.00

August 4, 2025 | americanbankingnews.com

FY2025 EPS Estimates for Vericel Decreased by Analyst

August 4, 2025 | marketbeat.com

Vericel (NASDAQ:VCEL) Posts Earnings Results, Beats Estimates By $0.03 EPS

August 3, 2025 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Short Interest Update

August 3, 2025 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Shares Sold by Baker Avenue Asset Management LP

August 3, 2025 | marketbeat.com

Vericel (NASDAQ:VCEL) Price Target Cut to $58.00 by Analysts at Canaccord Genuity Group

August 2, 2025 | marketbeat.com

Vericel (NASDAQ:VCEL) Hits New 52-Week Low - Here's What Happened

August 2, 2025 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Q2 2025 Earnings Call Transcript

August 2, 2025 | msn.com

Vericel Corporation Reports Strong Q2 2025 Earnings

August 1, 2025 | tipranks.com

Vericel (NASDAQ:VCEL) Shares Gap Down - Here's What Happened

August 1, 2025 | marketbeat.com

Earnings To Watch: Vericel Corp (VCEL) Reports Q2 2025 Result

August 1, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLDB, CGON, ADPT, and VCEL Company Descriptions

Adaptive Biotechnologies NASDAQ:ADPT

$13.00 +0.34 (+2.69%)

Closing price 04:00 PM Eastern

Extended Trading

$13.02 +0.02 (+0.12%)

As of 07:44 PM Eastern

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

CG Oncology NASDAQ:CGON

$26.49 +1.54 (+6.17%)

Closing price 04:00 PM Eastern

Extended Trading

$26.34 -0.15 (-0.56%)

As of 06:46 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Solid Biosciences NASDAQ:SLDB

$6.68 +0.64 (+10.60%)

Closing price 04:00 PM Eastern

Extended Trading

$6.76 +0.08 (+1.20%)

As of 07:16 PM Eastern

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Vericel NASDAQ:VCEL

$37.93 +1.39 (+3.80%)

Closing price 04:00 PM Eastern

Extended Trading

$37.66 -0.27 (-0.73%)

As of 04:53 PM Eastern

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time